Download

RESEARCH TRIANGLE PARK, N.C. & LONDON--(BUSINESS WIRE)--Quintiles and Sinclair IS Pharma today announced the signing of a
10-year collaboration and licensing agreement for Quintiles (Rowfarma
Mexico) to commercialize Sinclair’s portfolio of dermo-cosmetic products
and medical devices in Mexico.

Under the agreement, Quintiles will handle the entire process including
regulatory submissions; product importation, warehousing and
distribution to wholesalers; sales force promotion to dermatologists and
plastic surgeons; and marketing, advertising and promotion.

“This collaboration, a further step in Latin America, supports our
company’s growth strategy, to move our product portfolio into
fast-growing, emerging markets through strategic, regional
partnerships,” said Chris Spooner, Chief Executive Officer, Sinclair IS
Pharma. “Quintiles’ extensive commercialization experience and proven
track record in Mexico and other emerging markets made it the clear
choice to help us execute our strategy.”

The Sinclair portfolio consists of the following products: Atopiclair®
for the treatment of mild to moderate atopic dermatitis; Kelo-cote®
silicone-gel scar reduction range for the prevention and management of
abnormal scars; Sebclair® for the treatment of seborrhoeic dermatitis;
Bio-Taches® for hyperpigmentation disorders; XClair® for the treatment
of radiation dermatitis; and Papulex® for the management and maintenance
of mild to moderate acne.

“Our customers are thinking carefully about their strategy in emerging
markets, and are looking for a trusted partner who can help navigate the
complexities these markets present. With this agreement, Quintiles’ will
work on a wide range of services – from registration through to launch,
to help Sinclair expand its geographic footprint in a more predictable
manner,” said Quintiles Senior Vice President of Commercial Strategy
James Featherstone, Ph.D.

Cristobal Thompson, Country Manager for Quintiles Commercial Solutions
in Mexico, said: “We look forward to working with Sinclair to
commercialize these promising products in Mexico, a market that offers
significant business opportunities. With our 16-year heritage in Mexico,
our local market experience will complement Quintiles global systems and
standards, to help accelerate outcomes for Sinclair.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services
company offering clinical,
commercial,
consulting
and capital
solutions worldwide. Our network of more than 25,000 professionals in 60
countries has an eye on the future while delivering results today with
an unwavering commitment to patients, safety and ethics. Quintiles helps
biopharmaceutical companies develop and commercialize products to
improve and lengthen patients’ lives while demonstrating value to
stakeholders. Visit www.quintiles.com
for more information and www.quintiles.com/news
for additional company news.

Sinclair IS Pharma is an international specialty pharmaceutical company
focused on treatments in dermatology, wound care, oncology support and
critical care through advanced surface technology and innovative
delivery systems. The Company has a growing sales and marketing
operation with a direct sales presence in the top five European markets
and an extensive marketing partner network across selected developed and
emerging markets.